Valid Insight's New Appointments Confirm Its Strength in Market Access and Value

Press Release (ePRNews.com) - LONDON, England - Sep 05, 2017 - ​​​​​​​Just 18 months after its February 2016 launch, market access consultancy Valid Insight is pleased to announce the appointment of three new senior people to its rapidly expanding team. Tammy Wynne, Dominic Jones-Phillips and James Wright bring decades of specialist experience from industry.

Tammy Wynne joins as Director, Value Communication, leading a team of market access writers. She has over ten years’ experience in global market access consultancy and value communications. Tammy has held senior leadership positions at Covance Market Access and Medaxial. Working across a breadth of therapy areas, Tammy has conceptualized and delivered numerous projects for pharmaceutical, biotech and medical device companies, including market access strategy and competitor analysis, high impact communication materials, and training engagements. Tammy specialises in communicating product value in a form that will resonate with the myriad market access decision makers and stakeholders who influence them.

Dominic Jones-Phillips and James Wright will lead global pricing, reimbursement, and market access projects, responsible for research planning, analysis, and delivering strategic recommendations.

We have been through a period of phenomenal growth since our launch last year, and these three new hires will strengthen our offering even further, allowing us to bring a wider lens to help our clients optimise the commercial success of their products.

Steve Bradshaw, Managing Director

Dominic brings over ten years’ experience in industry and consulting. He began as a research scientist at Syngenta CTL, and gained experience in healthcare and payer dynamics across the EMEA, US/Canada and Asia Pacific pricing and reimbursement environment through senior positions at Apex Healthcare Consulting, DRG and Abacus International. Dominic has worked with pharmaceutical, biotech and medical device companies across multiple therapy areas and specialises in strategic pricing, reimbursement and payer launch strategy.

James brings twenty years’ experience in the healthcare industry, and worked at QuintilesIMS for 13 years in Consulting and Commercial Services. James has provided market access support to most of the top 25 pharmaceutical companies and has extensive experience in HTA optimization, evaluation of strategic pricing and market access implications for new launches, and product/portfolio lifecycle optimisation. James’ experience covers all major therapy areas, including rare and orphan disease, across established and emerging markets. He specialises in clinical trial assessment, payer positioning, value and pricing strategy and lifecycle management.

“We have been through a period of phenomenal growth since our launch last year, and these three new hires will strengthen our offering even further, allowing us to bring a wider lens to help our clients optimise the commercial success of their products,” said Steve Bradshaw, Valid Insight founder and managing director. “As our team expands, the wealth of industry experience at Valid Insight will deliver the insights that pharma and biotech need to create a better and stronger global healthcare landscape.”

About Valid Insight:
Valid Insight specialises in global market access consulting and helps pharmaceutical, biotech and medical device companies optimise market access across the product lifecycle. Valid Insight market access services are delivered by a team of industry experts who combine specialist medical, relevant commercial and market access expertise.​

Contact:

Valid Insight
Phone: +44 (0) 20 3750 9833
Email: discover@validinsight.com
www.validinsight.com

Source : Valid Insight
Business Info :
Valid Insight

You may also like this  

DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login